PMC6915153_01
Treatment timeline. *The numbers below the axis represent the number of months since the initial presentation. Abbreviations: NSCLC:non-small-cell lung cancer; Carbo:carboplatin; Pem:pemetrexed; Bev:bevacizumab; LUL:left upper lobe of the lung; PD:progression of disease; SD:stable disease; CR:complete response; PR:partial response; LN:lymph node; PDL-1:programmed death ligand-1; SIADH:syndrome of inappropriate antidiuretic hormone secretion.
CRIONM2019-1816472.001.jpg
PMC6915153_01_CRIONM2019-1816472.001.jpg
fig1
He was started on chemotherapy in January 2014 and received five cycles of carboplatin, pemetrexed, and bevacizumab, followed by three cycles of maintenance pemetrexed and bevacizumab (see Figure 1 for therapy sequence).
PET/CT images showing increased metabolic activity in the mediastinum (a) and in the liver (b) prior to initiating nivolumab. Resolution of FDG-avid lesions in the mediastinum (c) and in the liver (d) 10 months after discontinuation of nivolumab.
CRIONM2019-1816472.002.jpg
PMC6915153_01_CRIONM2019-1816472.002.jpg
fig2